Cyclosporine, Cyclophilins and HCV Replication
Cyclosporine, Cyclophilins and HCV Replication
批准号:
8309405
负责人:
HENGLI TANG
金额:
$32.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-04 至 2015-08-31
关键词:
AcuteAddressAffinityAntiviral AgentsBindingBiochemicalBiological AssayBiological ModelsC-terminalCell CommunicationCell Culture TechniquesCellsClinicalClinical TreatmentClinical TrialsComplexCyclophilin ACyclophilinsCyclosporineDNA-Directed RNA PolymeraseDataDependenceDevelopmentDiagnosticDrug resistanceEnsureFaceFibrosisGenotypeGoalsHealth systemHepatitis CHepatitis C virusHumanHuman VirusIn VitroInfectionInfection preventionInterferonsInterventionKnowledgeLeadLiver CirrhosisMapsMediator of activation proteinMessenger RNAMolecularMolecular Biology TechniquesMolecular ChaperonesMutagenesisMutationNonstructural ProteinParasitesPathway interactionsPatientsPharmaceutical PreparationsPlayPopulationPrimary carcinoma of the liver cellsProteinsRNA BindingResearchResistanceRoleSmall Interfering RNASurfaceTestingTherapeuticThumb structureVaccinesVariantViralViral GenomeVirusVirus ReplicationWorkanti-hepatitis Cbasechronic liver diseasecofactordrug candidateglobal healthhepatoma cellin vivoinsightinterferon therapymutantnew therapeutic targetnovelpathogenpositional cloningpreventprogramsprophylacticprotein functionreplicaseresearch studyresistant strainviral RNAviral resistance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The broad, long-term goal of our program is to advance the knowledge of virus-host cell
interactions by characterizing cellular cofactors essential for hepatitis C virus (HCV) infection.
HCV infects 170 million people worldwide and is major cause of hepatocellular carcinoma.
Understanding how this virus interacts with the host is of critical importance to the development
of diagnostics, antiviral drugs, and a prophylactic vaccine. Our previous studies demonstrated
that HCV infection of cultured hepatoma cells is critically dependent on a cellular protein,
cyclophilin A (CyPA), and that ablating the function of this protein can not only prevent new
infections but also suppress an existing infection. In addition, CyPA is a principal mediator of
HCV resistance to cyclosporine A (CsA) and its derivatives, which inhibit HCV replication with
an undefined mechanism and are currently being evaluated in clinical trials as candidate anti-
HCV drugs. The experiments proposed here will investigate the molecular mechanisms that
determine the essential cofactor function of CyPA, the action of CsA, and the related CsA
resistance. The following experiments will be performed: (1) CsA and small interfering RNA
directed at CyPA mRNA will be used to identify the specific function of HCV replicase that
requires CyPA as a cofactor. A detailed understanding of why and where the virus needs this
cellular chaperone to survive will offer new perspectives on the replication strategy of HCV. (2)
Biochemical assay and mutagenesis will be used to characterize the critical interaction between
CyPA and the viral replicase, which represents a novel structural interface of virus-host cell
interaction that maybe disrupted for therapeutic purposes. (3) Macromolecular interaction and
reverse genetics will be employed to dissect the mode of action for CsA and molecular basis of
CsA resistance with the ultimate goal of predicting and circumventing that resistance. The
results of the proposed studies will not only provide significant insights into how highly
successful parasites such as human viruses hijack host cell machineries to replicate efficiently
but also reveal new therapeutic targets for antiviral intervention.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3390/v5071684
发表时间:
2013-07-11
期刊:
Viruses
影响因子:
--
作者:
[Frausto SD, Lee E, Tang H]
通讯作者:
Tang H
DOI:
10.1371/journal.ppat.1001118
发表时间:
2010-09-23
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[Yang F, Robotham JM, Grise H, Frausto S, Madan V, Zayas M, Bartenschlager R, Robinson M, Greenstein AE, Nag A, Logan TM, Bienkiewicz E, Tang H]
通讯作者:
Tang H
Cyclophilin inhibitors as a novel HCV therapy.
亲环蛋白抑制剂作为一种新型 HCV 疗法。
DOI:
10.3390/v2081621
发表时间:
2010
期刊:
Viruses
影响因子:
--
作者:
[Tang,Hengli]
通讯作者:
Tang,Hengli
Perturbation of Host DNA Replication and Cell Cycle Progression by Zika Virus
-
批准号:10647724
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2019
-
负责人:HENGLI TANG
-
依托单位:
Perturbation of Host DNA Replication and Cell Cycle Progression by Zika Virus
-
批准号:10189506
-
项目类别:
-
资助金额:$37.89万
-
财政年份:2019
-
负责人:HENGLI TANG
-
依托单位:
Perturbation of Host DNA Replication and Cell Cycle Progression by Zika Virus
-
批准号:10426093
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2019
-
负责人:HENGLI TANG
-
依托单位:
Dissecting Dengue Virus Permissiveness using a Stem Cell Differentiation System
-
批准号:9089927
-
项目类别:
-
资助金额:$22.15万
-
财政年份:2015
-
负责人:HENGLI TANG
-
依托单位:
Dissecting Dengue Virus Permissiveness using a Stem Cell Differentiation System
-
批准号:8952031
-
项目类别:
-
资助金额:$18.39万
-
财政年份:2015
-
负责人:HENGLI TANG
-
依托单位:
Function of Lipid Droplets in Viral Entry and Membrane Fusion
-
批准号:8679468
-
项目类别:
-
资助金额:$22.03万
-
财政年份:2014
-
负责人:HENGLI TANG
-
依托单位:
Hepatic differentiation of stem cells and the cellular determinants of hepatitis
-
批准号:8728449
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2013
-
负责人:HENGLI TANG
-
依托单位:
Cyclosporine, Cyclophilins and HCV Replication
-
批准号:7925735
-
项目类别:
-
资助金额:$32.45万
-
财政年份:2009
-
负责人:HENGLI TANG
-
依托单位:
Cyclosporine, Cyclophilins and HCV Replication
-
批准号:8120232
-
项目类别:
-
资助金额:$32.13万
-
财政年份:2009
-
负责人:HENGLI TANG
-
依托单位:
Cyclosporine, Cyclophilins and HCV Replication
-
批准号:7731590
-
项目类别:
-
资助金额:$32.78万
-
财政年份:2009
-
负责人:HENGLI TANG
-
依托单位:
CELLULAR COFACTOR FOR CONSTITUTIVE TRANSPORT ELEMENT OF TYPE D RETROVIRUS: HIV
-
批准号:6252939
-
项目类别:
-
资助金额:$1.9万
-
财政年份:1997
-
负责人:HENGLI TANG
-
依托单位:
Modeling Zika virus pathogenesis and potential intervention during neural development using a human brain organoid system
-
批准号:9312473
-
项目类别:
-
资助金额:$38.78万
-
财政年份:--
-
负责人:HENGLI TANG
-
依托单位:
Modeling Zika virus pathogenesis and potential intervention during neural development using a human brain organoid system
-
批准号:9913466
-
项目类别:
-
资助金额:$35.83万
-
财政年份:--
-
负责人:HENGLI TANG
-
依托单位:
海外基金